Researcher
Julia Katharina Schwarze
- Keywords:Medicine
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Sep 2018 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From28 Sep 2015 → Today - Internal medicine (Department)
Member
From1 Oct 2023 → Today - Clinical sciences (Department)
Member
From1 Jun 2022 → Today - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 May 2022 - Internal medicine (Department)
Member
From1 Sep 2018 → 30 Sep 2022 - Medical Oncology (Department)
Member
From2 Jul 2018 → 31 Aug 2018 - Clinical sciences (Department)
Member
From1 Jun 2018 → 31 May 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From11 May 2018 → 14 Dec 2023 - Faculty of Medicine and Pharmacy (Faculty)
Member
From21 Sep 2012 → 26 Jun 2014
Publications
1 - 10 of 26
- ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy(2024)
Authors: Victor A Arrieta, Johnny Duerinck, Kirsten B Burdett, Karl J Habashy, Wietse Geens, Andrew Gould, Julia Katharina Schwarze, Crismita Dmello, Kwang-Soo Kim, Ruth Saganty, et al.
Pages: 379-388 - Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma(2024)
Authors: Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, et al.
- Current "state of the art" on dendritic cell-based cancer vaccines in melanoma(2023)
Authors: Julia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts, Bart Neyns
Pages: 87-93 - Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Authors: Julia Katharina Schwarze, Jens Tijtgat, G Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pages: 1-13 - Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma(2022)
Authors: Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander N Shoushtari, Anne Zaremba, Judith M Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, et al.
- A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Authors: G Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pages: 183-191 - Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells(2022)
Authors: Philipp Kalus, Jolien De Munck, Sarah Vanbellingen, Laura Carreer, Thessa Laeremans, Katrijn Broos, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Bart Neyns, et al.
- Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Authors: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, G Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Authors: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, K Breckpot, Joeri Aerts, Bart Neyns, Sandra Tuyaerts
- C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Authors: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, G Awada, Valérie Vandersleyen, Sandrine Aspeslagh, Bart Neyns
Pages: 371-377